Reasonable To Worry After Sinovac Incidents: Expert
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1579558_1_20210309121230.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1579558-20210309.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1579558-20210309.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-03-09 HKT 12:30
Benjamin Cowling talks to RTHK's Janice Wong
A leading epidemiologist said on Tuesday that it is reasonable for people to be worried about reports of deaths and hospitalisations among those who have received a coronavirus vaccine made by China's Sinovac, and there just isn't that much data available regarding this particular jab.
Professor Benjamin Cowling from the University of Hong Kong noted that around 100,000 people have so far received the Sinovac vaccine in the SAR and the number of deaths has been "really small". But he added that the recent incidents – including three deaths – are concerning.
"It's possible that they [the deaths] are coincidental. But at the same time, it's reasonable to be worried about whether there might be a link between the vaccine and some of the events we've heard about," he told RTHK's Janice Wong.
Cowling said nowhere has much experience regarding the effects of the Sinovac jab on the elderly, and transparency from the SAR government is vital.
"Other parts of the world have been using other vaccines, particularly the BioNTech vaccine and the AstraZeneca vaccine, and we haven't heard too much about concerns of adverse reactions in the days following vaccination," he said.
"For Sinovac, I'm a little bit uncertain about what's the right step next, because we don't have a lot of international experience to rely on with that vaccine."
Asked what the government should do to address public concerns about Covid inoculations, Cowling said it is important to remember that Hong Kong also has BioNTech jabs available.
He said Hong Kong would achieve a higher level of immunity against Covid-19 if people chose this German-made vaccine, adding that he would echo advice that older people with underlying medical conditions should stay away from the Sinovac jab.
StartmeupHK Festival And Hong Kong Fintech Week 2025 Merge For 10th Anniversary Milestone
Invest Hong Kong (InvestHK) announced on 10 March 2025 that both of its flagship events, Hong Kong Fintech Week 2025 an... Read more
Ant AI-Powered Health Insurance Processes 7.25M Claims In 2024, 55%YoY Increase
In 2024, Ant Insurance, the online insurance brokerage platform of Ant Group, processed 7.25 million health claims, mar... Read more
Ping An Talent Uses AI For Job Matching, But Can Technology Make Recruitment Fairer?
Ping An Insurance (Group) Company of China, Ltd. has launched its 2025 Spring Campus Recruitment, offering over 2,000 p... Read more
HKEX Partners With CMU OmniClear To Boost Post-Trade Securities Infrastructure
Hong Kong Exchanges and Clearing Limited (HKEX) announced on 4 March 2025 that it signed a Memorandum of Understanding ... Read more
PAObank Secures Insurance Agency Licence, Partners With Ping An And FWD Hong Kong
PAO Bank Limited (PAObank) has received its Insurance Agency Licence from the Insurance Authority and signed strategic ... Read more
IFAST Launches Self-Service Accounts For Hong Kong Family Offices
Fintech solutions provider iFAST HK launches self-service accounts in Hong Kong, catering to the growing demand for ind... Read more